

**REMARKS/ARGUMENTS**

This is a Supplemental Response to the Official Action dated April 11, 2003 and the Advisory Action dated July 24, 2003. After amendment of the claims as indicated above, claims 20-24, 27-32, and 55-58 will remain pending in this application. Claim 20 has been amended to incorporate the elements of claim 17.<sup>1</sup> Claims 17 and 26 have been canceled, without prejudice, and Applicant expressly reserves the right to file and prosecute these claims in any subsequent continuation or divisional applications. No claims have been added in this amendment.

Applicant wishes to thank the Examiner for taking the time for a phone conference on August 21, 2003. At that time the Examiner indicated that her search during the prosecution of this application was limited to Group IV compounds. Because of this, the Examiner indicated that if Applicant was to limit the claims at this time to the method of claim 17 utilizing the compounds of claim 20, the case would likely be allowed. Applicant, therefore, has amended claim 20 to incorporate the methods steps of claim 17. Accordingly, reconsideration of the application and a notice of allowance are respectfully requested.

---

<sup>1</sup> Applicant notes that the elements incorporated into claim 20 include the proposed amendment to claim 17 set out in Applicant's July 3, 2003 Response (*i.e.*, substituting "the concentration of radioactivity within" for "a physical property of" in element b). The July 24, 2003 Advisory Action indicates that this amendment was not entered at that time.

**DOCKET NO.:** DM6993/BMS-0689  
**Application No.:** 09/534,893  
**Office Action Dated:** April 11, 2003

**PATENT  
REPLY FILED UNDER EXPEDITED  
PROCEDURE PURSUANT TO  
37 CFR § 1.116**

**CONCLUSION**


Applicant believes that the foregoing constitutes a complete and full response to the Office Action of record. An early and favorable consideration of the present application is respectfully requested.

Please continue to send all correspondence to:

Bristol-Myers Squibb Pharmaceutical Company  
P.O. Box 4000  
Princeton, New Jersey 08543-4000  
Telephone: (302) 467-5260  
Facsimile: (302) 467-6701

Respectfully submitted,

Date: September 9, 2003

  
Steven D. Maslowski  
Registration No. 46,905

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439